These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

467 related items for PubMed ID: 23601333

  • 1. Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial.
    Gupta N, Kumar A, Sharma P, Garg V, Sharma BC, Sarin SK.
    Liver Int; 2013 Sep; 33(8):1148-57. PubMed ID: 23601333
    [Abstract] [Full Text] [Related]

  • 2. Reduction of variceal pressure by propranolol: comparison of the effects on portal pressure and azygos blood flow in patients with cirrhosis.
    Feu F, Bordas JM, Luca A, García-Pagán JC, Escorsell A, Bosch J, Rodés J.
    Hepatology; 1993 Nov; 18(5):1082-9. PubMed ID: 8225212
    [Abstract] [Full Text] [Related]

  • 3. Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis.
    Bañares R, Moitinho E, Piqueras B, Casado M, García-Pagán JC, de Diego A, Bosch J.
    Hepatology; 1999 Jul; 30(1):79-83. PubMed ID: 10385642
    [Abstract] [Full Text] [Related]

  • 4. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol.
    Reiberger T, Ulbrich G, Ferlitsch A, Payer BA, Schwabl P, Pinter M, Heinisch BB, Trauner M, Kramer L, Peck-Radosavljevic M, Vienna Hepatic Hemodynamic Lab.
    Gut; 2013 Nov; 62(11):1634-41. PubMed ID: 23250049
    [Abstract] [Full Text] [Related]

  • 5. Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding.
    Villanueva C, Aracil C, Colomo A, Hernández-Gea V, López-Balaguer JM, Alvarez-Urturi C, Torras X, Balanzó J, Guarner C.
    Gastroenterology; 2009 Jul; 137(1):119-28. PubMed ID: 19344721
    [Abstract] [Full Text] [Related]

  • 6. Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: a case-control study.
    Schepis F, Vukotic R, Berzigotti A, Carrión JA, Forns X, Abraldes JG, García-Valdecasas JC, Navasa M, García-Pagán JC, Bosch J.
    Liver Transpl; 2013 Apr; 19(4):450-6. PubMed ID: 23408436
    [Abstract] [Full Text] [Related]

  • 7. VSL#3 ® probiotic therapy does not reduce portal pressures in patients with decompensated cirrhosis.
    Jayakumar S, Carbonneau M, Hotte N, Befus AD, St Laurent C, Owen R, McCarthy M, Madsen K, Bailey RJ, Ma M, Bain V, Rioux K, Tandon P.
    Liver Int; 2013 Nov; 33(10):1470-7. PubMed ID: 23968203
    [Abstract] [Full Text] [Related]

  • 8. Portal pressure response to losartan compared with propranolol in patients with cirrhosis.
    De BK, Bandyopadhyay K, Das TK, Das D, Biswas PK, Majumdar D, Mandal SK, Ray S, Dasgupta S.
    Am J Gastroenterol; 2003 Jun; 98(6):1371-6. PubMed ID: 12818283
    [Abstract] [Full Text] [Related]

  • 9. Propranolol in the prevention of the first hemorrhage from esophagogastric varices: A multicenter, randomized clinical trial. The Boston-New Haven-Barcelona Portal Hypertension Study Group.
    Conn HO, Grace ND, Bosch J, Groszmann RJ, Rodés J, Wright SC, Matloff DS, Garcia-Tsao G, Fisher RL, Navasa M.
    Hepatology; 1991 May; 13(5):902-12. PubMed ID: 2029994
    [Abstract] [Full Text] [Related]

  • 10. [A randomized placebo-controlled multicentre study of Fuzhenghuayu capsule for prevention of oesophageal variceal bleeding in patients with liver cirrhosis].
    Xiao D, Gu J, Cai H, Zhang Q, Xue D, Zhao C, Xu L.
    Zhonghua Gan Zang Bing Za Zhi; 2014 Aug; 22(8):594-9. PubMed ID: 25243960
    [Abstract] [Full Text] [Related]

  • 11. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.
    Abraldes JG, Albillos A, Bañares R, Turnes J, González R, García-Pagán JC, Bosch J.
    Gastroenterology; 2009 May; 136(5):1651-8. PubMed ID: 19208350
    [Abstract] [Full Text] [Related]

  • 12. Comparative randomized study on efficacy of losartan versus propranolol in lowering portal pressure in decompensated chronic liver disease.
    Agasti AK, Mahajan AU, Phadke AY, Nathani PJ, Sawant P.
    J Dig Dis; 2013 May; 14(5):266-71. PubMed ID: 23280243
    [Abstract] [Full Text] [Related]

  • 13. Effects of probiotic therapy on portal pressure in patients with cirrhosis: a pilot study.
    Tandon P, Moncrief K, Madsen K, Arrieta MC, Owen RJ, Bain VG, Wong WW, Ma MM.
    Liver Int; 2009 Aug; 29(7):1110-5. PubMed ID: 19490420
    [Abstract] [Full Text] [Related]

  • 14. A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis.
    Kim SG, Kim TY, Sohn JH, Um SH, Seo YS, Baik SK, Kim MY, Jang JY, Jeong SW, Lee B, Kim YS, Suk KT, Kim DJ.
    Am J Gastroenterol; 2016 Nov; 111(11):1582-1590. PubMed ID: 27575713
    [Abstract] [Full Text] [Related]

  • 15. Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: A randomized controlled trial.
    Pollo-Flores P, Soldan M, Santos UC, Kunz DG, Mattos DE, da Silva AC, Marchiori RC, Rezende GF.
    Dig Liver Dis; 2015 Nov; 47(11):957-63. PubMed ID: 26321186
    [Abstract] [Full Text] [Related]

  • 16. Hepatic venous pressure gradient measurement in patients with liver cirrhosis: a correlation with disease severity and variceal bleeding.
    Silkauskaite V, Pranculis A, Mitraite D, Jonaitis L, Petrenkiene V, Kupcinskas L.
    Medicina (Kaunas); 2009 Nov; 45(1):8-13. PubMed ID: 19223700
    [Abstract] [Full Text] [Related]

  • 17. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial.
    Dhiman RK, Rana B, Agrawal S, Garg A, Chopra M, Thumburu KK, Khattri A, Malhotra S, Duseja A, Chawla YK.
    Gastroenterology; 2014 Dec; 147(6):1327-37.e3. PubMed ID: 25450083
    [Abstract] [Full Text] [Related]

  • 18. 5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial.
    Vukotic R, Di Donato R, Roncarati G, Simoni P, Renzulli M, Gitto S, Schepis F, Villa E, Berzigotti A, Bosch J, Andreone P.
    J Hepatol; 2023 Oct; 79(4):977-988. PubMed ID: 37482222
    [Abstract] [Full Text] [Related]

  • 19. NCX-1000, a nitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study.
    Berzigotti A, Bellot P, De Gottardi A, Garcia-Pagan JC, Gagnon C, Spénard J, Bosch J.
    Am J Gastroenterol; 2010 May; 105(5):1094-101. PubMed ID: 19920806
    [Abstract] [Full Text] [Related]

  • 20. Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: A preliminary study.
    Abecasis R, Kravetz D, Fassio E, Ameigeiras B, Garcia D, Isla R, Landeira G, Dominguez N, Romero G, Argonz J, Terg R.
    Hepatology; 2003 Feb; 37(2):359-65. PubMed ID: 12540786
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.